LionKingAir
2022-04-06

$Bioxcel Therapeutics Inc.(BTAI)$Shares of BioXcel Therapeutics Inc. (BTAI) jumped 14.6% in premarket trading on Wednesday after the company said the Food and Drug Administration approved Igalmi, a sublingual film used to treat agitation associated with schizophrenia or bipolar disorder in adults. The therapy is expected to launch in the U.S. in the second quarter of this year. BioXcel's stock is down 2.2% so far this year, while the broader S&P 500 has declined 5.0%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • VirgilLouis
    2022-04-06
    VirgilLouis
    In fact, many young people have this problem nowadays and I am optimistic about this company's business.
  • FredLee
    2022-04-06
    FredLee
    It can treat schizophrenia and bipolar disorder. I think this drug has a good market.
  • VivianField
    2022-04-06
    VivianField
    This biomedical technology company is very good and has given a performance before the market.
  • R2D2
    2022-05-01
    R2D2
    will research further.  thanks
  • JLKang
    2022-05-01
    JLKang
    Can be volatile
  • Dorcasnoobie
    2022-05-01
    Dorcasnoobie

    [Miser] 

Leave a comment
3